Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1080/17512433.2024.2447779 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
FLOT vs CROSS in localized esophageal adenocarcinoma: what is the current best strategy?
Expert Rev Clin Pharmacol
January 2025
Department of Gastrointestinal Medical Oncology, U.T. M.D. Anderson Cancer Center, Houston, TX, USA.
Current Standards and Controversies in Multidisciplinary Management of Locoregional Gastroesophageal Junction Tumors.
Curr Oncol Rep
December 2024
Department of Radiation Oncology, The University of Texas Southwestern Medical Center, Dallas, TX, USA.
Purpose Of Review: There has been controversy in the management of gastroesophageal (GE) junction cancers with pre-operative chemoradiation and peri-operative chemotherapy as accepted practices. We aim to assess and compare the defining trials establishing current standards of care and discuss future directions seeking to further improve patient-centered outcomes in GE junction cancers.
Recent Findings: Over the last two decades, several large Phase III randomized trials have been conducted including GE junction cancers, showing superiority of 1) pre-operative chemoradiation over surgery (CROSS) and 2) peri-operative chemotherapy with FLOT over CROSS without radiotherapy (FLOT 4).
Definition and Predictors of Early Recurrence in Neoadjuvantly Treated Esophageal and Gastroesophageal Adenocarcinoma: a Dual-Center Retrospective Cohort Study.
Ann Surg Oncol
November 2024
Department of General, Visceral and Transplantation Surgery, Heidelberg University Hospital, Heidelberg, Germany.
Abstarct: BACKGROUND: Early recurrence after esophagectomy is often used as a surrogate for aggressive tumor biology and treatment failure. However, there is no standardized definition of early recurrence, and predictors for early recurrence are unknown. Therefore, we aimed to define an evidence-based cutoff to discriminate early and late recurrence and assess the influence of neoadjuvant treatment modalities for patients with esophageal or gastroesophageal-junction adenocarcinoma (EAC).
View Article and Find Full Text PDFRisk of cardiac arrhythmias and outcomes with perioperative FLOT vs CROSS regimens for esophageal adenocarcinoma.
Heart Rhythm
October 2024
Division of Hematology, Oncology, and Blood and Marrow Transplantation, University of Iowa Hospitals and Clinics, Iowa City, Iowa. Electronic address:
Outcomes of locally advanced gastric and gastroesophageal adenocarcinoma cancers treated with neoadjuvant FLOT in a tertiary care hospital in Pakistan.
Ecancermedicalscience
May 2024
Department of Medical Oncology, Aga Khan University Hospital, Karachi 74800, Pakistan.
Background And Aim: Docetaxel, oxaliplatin, leucovorin and 5-fluorouracil (FLOT) may improve overall survival (OS) in patients with locally advanced gastric and gastroesophageal cancer. Our study aims to determine the pathological response in these patients with the FLOT chemotherapy in the Neoadjuvant setting. This is the first study conducted in our country.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!